Fortress Biotech Inc (FBIO)vsNovartis AG ADR (NVS)
FBIO
Fortress Biotech Inc
$2.28
0.00%
HEALTHCARE · Cap: $84.04M
NVS
Novartis AG ADR
$145.46
+1.32%
HEALTHCARE · Cap: $271.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 82705% more annual revenue ($56.69B vs $68.47M). FBIO leads profitability with a 163.3% profit margin vs 22.5%. FBIO trades at a lower P/E of 0.9x. FBIO earns a higher WallStSmart Score of 57/100 (C).
FBIO
Buy57
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+73.4%
Fair Value
$13.79
Current Price
$2.28
$11.51 discount
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.46
$52.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 163 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -108.7% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIO
The strongest argument for FBIO centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : FBIO
The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
FBIO profiles as a mature stock while NVS is a value play — different risk/reward profiles.
FBIO carries more volatility with a beta of 1.19 — expect wider price swings.
FBIO is growing revenue faster at 14.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
FBIO scores higher overall (57/100 vs 51/100), backed by strong 163.3% margins and 14.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?